PTPN2 and breast cancer: For immunogenic tumors with abundant T cell infiltrates, such as AT3-OVA mammary tumors, Compound 182 might largely repress tumor growth by acting directly on T cells, since the effects of the inhibitor could be largely phenocopied by deleting either PTP1B or PTPN2 in T cells and this was not further enhanced by the administration of Compound 182.